Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans

To compare the effects of the kappa-opioid agonist asimadoline and placebo on visceral sensation and gastrointestinal (GI) motor functions in humans, 91 healthy participants were randomized in a double-blind fashion to 0.15, 0.5, or 1.5 mg of asimadoline or placebo orally twice a day for 9 days. We...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of physiology: Gastrointestinal and liver physiology Vol. 284; no. 4; pp. G558 - G566
Main Authors Delgado-Aros, Silvia, Chial, Heather J, Camilleri, Michael, Szarka, Lawrence A, Weber, Frank T, Jacob, Jutta, Ferber, Irene, McKinzie, Sanna, Burton, Duane D, Zinsmeister, Alan R
Format Journal Article
LanguageEnglish
Published United States 01.04.2003
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:To compare the effects of the kappa-opioid agonist asimadoline and placebo on visceral sensation and gastrointestinal (GI) motor functions in humans, 91 healthy participants were randomized in a double-blind fashion to 0.15, 0.5, or 1.5 mg of asimadoline or placebo orally twice a day for 9 days. We assessed satiation (nutrient drink test), colonic compliance, tone, perception of colonic distension (barostat), and whole gut transit (scintigraphy). Treatment effect was assessed by analysis of covariance. Asimadoline increased nutrient drink intake (P = 0.03). Asimadoline decreased colonic tone during fasting (P = 0.03) without affecting postprandial colonic contraction, compliance, or transit. Gas scores in response to colonic distension were decreased with 0.5 mg of asimadoline at low levels (8 mmHg above operating pressure) of distension (P = 0.04) but not at higher levels of distension. Asimadoline at 1.5 mg increased gas scores at 16 mmHg of distension (P = 0.03) and pain scores at distensions of 8 and 16 mmHg (P = 0.003 and 0.03, respectively) but not at higher levels of distension. Further studies of this compound in diseases with altered satiation or visceral sensation are warranted.
ISSN:0193-1857
1522-1547
DOI:10.1152/ajpgi.00360.2002